Cargando…

Emerging therapies for breast cancer

HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xichun, Huang, Wei, Fan, Minhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410098/
https://www.ncbi.nlm.nih.gov/pubmed/28454587
http://dx.doi.org/10.1186/s13045-017-0466-3